Aptevo Therap | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -2.23, missing the estimate of USD -2.09.

EBIT: As of FY2025 Q3, the actual value is USD -7.671 M.

Cash Position

• Aptevo Therapeutics Inc. had cash and cash equivalents totaling $21.1 million as of September 30, 2025. During the third quarter, the company raised $18.7 million, net, and an additional $4.1 million, net, in October, bringing the proforma cash and cash equivalents to $25.2 million.

Research and Development Expenses

• Research and development expenses increased by $0.9 million, from $3.1 million for the three months ended September 30, 2024, to $4.0 million for the three months ended September 30, 2025. The increase was primarily due to increased mipletamig and employee costs, offset by lower costs on ALG.APV-527.

General and Administrative Expenses

• General and administrative expenses increased by $1.5 million, from $2.1 million for the three months ended September 30, 2024, to $3.6 million for the three months ended September 30, 2025. The increase is primarily due to higher employee costs.

Net Income (Loss)

• Aptevo had a net loss of $7.5 million or $2.23 per share for the three months ended September 30, 2025, compared to a net loss of $5.1 million or $357.86 per share for the corresponding period in 2024.

Dividend Attributable to Down Round Feature of Warrants

• The $1.5 million recorded in the three months ended September 30, 2025, reflects a dividend deemed to common shareholders, increasing the net loss attributable to common shareholders to $9.0 million for EPS purposes.

Outlook / Guidance

• Aptevo raised $22.8 million since the end of the second quarter, extending its runway well into the fourth quarter of 2026. This additional capital positions the company to execute on its clinical and development plans while remaining focused on delivering value for patients and shareholders.